AstraZeneca: DECLARE-TIMI Outcomes May Support Competitive Claim For Farxiga In Heart Failure
Executive Summary
Lack of significant reduction on cardiovascular deaths or a composite of major events may have been due to enrollment of a healthier population relative to other studies, said investigators from the DECLARE-TIMI 58 outcomes study, which was reported at the AHA meeting.
You may also be interested in...
Keeping Track: Vertex’ Trikafta Speeds To US Approval; New Indications For AZ’s Farxiga, J&J’s Stelara, GSK’s Zejula
The latest drug development news and highlights from our US FDA Performance Trackers.
AstraZeneca’s Farxiga Approval In Heart Failure A First For SGLT2 Inhibitors
Farxiga, with a new indication to prevent hospitalization for heart failure in type 2 diabetes patients, is the first drug among the SGLT2 class to gain this indication outside of diabetics with renal disease.
AZ's Farxiga Fillip As Drug Reduces Renal Disease Risk In Type 2 Diabetics
AstraZeneca has presented more data on Farxiga at the American Diabetes Association meeting which should help the SGLT2 inhibitor in its battles with Jardiance and Invokana.